ArticleAmerican journal of translational research2025
Effects of regional citrate anticoagulation on clinical outcome and complications in continuous renal replacement therapy for acute kidney injury.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of regional citrate anticoagulation (RCA) on clinical outcome, renal function, and bleeding complications in patients with acute kidney injury (AKI) undergoing continuous renal replacement therapy (CRRT).
methodsThis retrospective study reviewed medical records of 180 patients treated at the Second Affiliated Hospital of Hainan Medical University from January 2020 to January 2023. Patients were divided into two groups based on anticoagulation strategy: 85 patients who received systemic heparin anticoagulation (control group, CG) and 95 patients who received RCA (research group, RG). The clinical efficacy, adverse reactions, and incidence of bleeding complications were compared between the groups. Changes in renal function [blood urea nitrogen (BUN) and serum creatinine (Scr)] and coagulation values [prothrombin time (PT), activated partial thromboplastin time (APTT), and platelet count (PLT)] before and after treatment were also analyzed.
resultsThe total effective rate was significantly higher in the RG compared to the CG (P<0.05). The incidence of adverse reactions was 12.94% in the CG and 8.42% in the RG, with no statistically significant difference (P>0.05). However, the incidence of bleeding complications was significantly lower in the RG (P<0.05). After treatment, both groups showed significant reductions in BUN and Scr, with the RG exhibiting lower levels than the CG (both P<0.05). In both groups, PT and APTT increased while PLT decreased, but these values were more favorable in the RG (all P<0.05). Logistic regression analysis identified age, AKI stage, and treatment method as independent risk factors influencing treatment efficacy (all P<0.05). Additionally, post-treatment levels of hypersensitive C-reactive protein (hs-CRP) and interleukin-4 (IL-4) decreased in both groups, with the RG showing significantly lower levels than the CG (all P<0.05).
conclusionRCA is effective for AKI patients undergoing CRRT, improving renal and coagulation function, reducing the risk of adverse reactions and bleeding, and demonstrating a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.